Want to see XBIO full AI Analyst Report?
XBIO Stock Chart & Stats
$2.64
-$0.14(-5.30%)
At close: 4:00 PM EDT
$2.64
-$0.14(-5.30%)
Day’s Range― - ―
52-Week Range$1.90 - $13.93
Previous Close$2.64
Volume3.06K
Average Volume (3M)1.70M
Market Cap
$8.41M
Enterprise Value$0.20
Total Cash (Recent Filing)$6.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding2,343,181
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong revenue expansion indicates growing commercial or partnership-related activity. If sustained, this can broaden the company’s operating base and improve its ability to absorb fixed research and corporate costs over time.
High Gross MarginA high reported gross margin suggests revenue carries limited direct delivery costs, creating potential operating leverage as activity scales. This benefit is meaningful if the company can convert revenue growth into lower operating losses.
Debt-Free Balance SheetNo debt reduces interest obligations, refinancing exposure, and balance-sheet stress while the pipeline remains in development. This gives management greater flexibility to allocate available capital toward technology development and strategic opportunities.
Bears Say
Persistent LossesDeep operating losses show that current revenue is insufficient to cover research, development, and corporate expenses. Until the pipeline or licensing activities scale materially, earnings may remain dependent on uncertain future milestones or financing.
Ongoing Cash BurnNegative operating and free cash flow indicates the business is not yet self-funding. Continued development spending may require external capital, creating funding dependence and potential dilution unless cash generation improves sustainably.
Declining Shareholders' EquityThe sustained reduction in equity reflects accumulated losses and weaker financial capacity. It can limit flexibility for clinical development and increase the likelihood that future operations or strategic initiatives require additional capital.
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.90 and its highest was $13.93 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $8.41M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is Nov 06, 2026 which is in 75 days.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on Aug 07, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,343,181 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.41 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 11.228%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Technical Analysis
Ownership Overview
4.27% Insiders
0.85% Mutual Funds
0.12% Other Institutional Investors
94.23% Public Companies and
Individual Investors